Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies.

Abstract:

OBJECTIVE:Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an interdisciplinary effort. The present study was conducted to condense essential strategies from a single neurovascular centre with regard to the lessons learned. METHOD:Medical charts of 321 consecutive patients treated for IAs at our centre from September 2008 until December 2010 were retrospectively analysed for clinical presentation of the aneurysms, multiplicity and treatment pathways. In addition, a selective Medline search was performed. RESULTS:A total of 321 patients with 492 aneurysms underwent occlusion of their symptomatic aneurysm: 132 (41.1%) individuals were treated surgically, 189 (58.2%) interventionally; 138 patients presented with a SAH, of these 44.2% were clipped and 55.8% were coiled. Aneurysms of the middle cerebral artery were primarily occluded surgically (88), whereas most of the aneurysms of the internal carotid artery and anterior communicating artery (114) were treated endovascularly. Multiple aneurysms (range 2-5 aneurysms/individual) were diagnosed in 98 patients (30.2%). During the study period 12 patients with recurrent aneurysms were allocated to another treatment modality (previously clip to coil and vice versa). CONCLUSIONS:Our data show that successful interdisciplinary occlusion of IAs is based on both neurosurgical and neurointerventional therapy. In particular, multiple and recurrent aneurysms require tailored individual approaches to aneurysmal occlusion. This is achieved by a consequent interdisciplinary pondering of the optimal strategy to occlude IAs in order to prevent SAH.

journal_name

Ther Adv Neurol Disord

authors

Mueller OM,Schlamann M,Mueller D,Sandalcioglu IE,Forsting M,Sure U

doi

10.1177/1756285611415309

subject

Has Abstract

pub_date

2011-09-01 00:00:00

pages

267-79

issue

5

eissn

1756-2856

issn

1756-2864

pii

10.1177_1756285611415309

journal_volume

4

pub_type

杂志文章
  • Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.

    abstract:Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286420918088

    authors: Gklinos P,Mitsikostas DD

    更新日期:2020-04-28 00:00:00

  • Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis.

    abstract:OBJECTIVES:The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS:We conducted a systematic ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285616650357

    authors: Tsivgoulis G,Katsanos AH,Magoufis G,Kargiotis O,Papadimitropoulos G,Vadikolias K,Karapanayiotides T,Ellul J,Alexandrov AW,Mitsias PD,Alexandrov AV

    更新日期:2016-09-01 00:00:00

  • Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study.

    abstract:Background:To compare the long-term clinical outcomes of different antihypertensive drugs in stable patients after acute hemorrhagic stroke (HS). Methods:From January 2001 to December 2013, patients with first-ever primary HS were identified in the National Health Insurance Research Database, Taiwan. Patients with tra...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418802688

    authors: Liu CH,Lin YS,Chi CC,Liou CW,Lee JD,Peng TI,Lee TH

    更新日期:2018-09-28 00:00:00

  • Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis.

    abstract:Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419838673

    authors: Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

    更新日期:2019-04-24 00:00:00

  • Hypothalamic deep brain stimulation in the treatment of chronic cluster headache.

    abstract::Cluster headache (CH) is a short-lasting unilateral headache associated with ipsilateral craniofacial autonomic manifestations. A positron emission tomography (PET) study has shown that the posterior hypothalamus is activated during CH attacks, suggesting that hypothalamic hyperactivity plays a key role in CH pathophy...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285610370722

    authors: Leone M,Franzini A,Cecchini AP,Broggi G,Bussone G

    更新日期:2010-05-01 00:00:00

  • Application of immunotherapy for neurological manifestations in hypermobile Ehlers-Danlos syndrome.

    abstract::Ehlers-Danlos syndrome (EDS) is a heterogeneous heritable connective tissue disorder with various neurological manifestations, including chronic pain. The neurological manifestations in EDS are often regarded as being caused by the associated musculoskeletal disorders or polyneuropathy. Here, we present two patients w...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286418793766

    authors: Araki M,Lin Y,Ono H,Sato W,Yamamura T

    更新日期:2018-08-18 00:00:00

  • Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.

    abstract::The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285616640684

    authors: Tallner A,Pfeifer K,Mäurer M

    更新日期:2016-07-01 00:00:00

  • Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

    abstract::Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reacti...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608100325

    authors: Haussleiter IS,Brüne M,Juckel G

    更新日期:2009-01-01 00:00:00

  • Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management.

    abstract::Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since th...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418789340

    authors: Ramiro L,Simats A,García-Berrocoso T,Montaner J

    更新日期:2018-08-06 00:00:00

  • Neutralizing antibodies against interferon-Beta.

    abstract::The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608095144

    authors: Sorensen PS

    更新日期:2008-09-01 00:00:00

  • Diagnosis and treatment of impulse control disorders in patients with movement disorders.

    abstract::Impulse control disorders are a psychiatric condition characterized by the failure to resist an impulsive act or behavior that may be harmful to self or others. In movement disorders, impulse control disorders are associated with dopaminergic treatment, notably dopamine agonists (DAs). Impulse control disorders have b...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613476127

    authors: Mestre TA,Strafella AP,Thomsen T,Voon V,Miyasaki J

    更新日期:2013-05-01 00:00:00

  • Wernicke-Korsakoff syndrome associated with mtDNA disease.

    abstract:Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420938972

    authors: Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

    更新日期:2020-07-30 00:00:00

  • C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

    abstract:Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420935697

    authors: Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

    更新日期:2020-08-10 00:00:00

  • Advances in spinal muscular atrophy therapeutics.

    abstract::Spinal muscular atrophy (SMA) is a progressive, recessively inherited neuromuscular disease, characterized by the degeneration of lower motor neurons in the spinal cord and brainstem, which leads to weakness and muscle atrophy. SMA currently represents the most common genetic cause of infant death. SMA is caused by th...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285618754501

    authors: Parente V,Corti S

    更新日期:2018-02-05 00:00:00

  • Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.

    abstract:BACKGROUND:Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation increases a drug's half life and exposure, and may also reduce immunogen...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285616633967

    authors: White JT,Newsome SD,Kieseier BC,Bermel RA,Cui Y,Seddighzadeh A,Hung S,Crossman M,Subramanyam M

    更新日期:2016-07-01 00:00:00

  • Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord.

    abstract::Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420909973

    authors: Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

    更新日期:2020-06-03 00:00:00

  • Current and emerging therapies in multiple sclerosis: a systematic review.

    abstract::Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that preven...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612450936

    authors: Castro-Borrero W,Graves D,Frohman TC,Flores AB,Hardeman P,Logan D,Orchard M,Greenberg B,Frohman EM

    更新日期:2012-07-01 00:00:00

  • HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series.

    abstract:Background:To investigate outcome and toxicity of high-dose systemic methotrexate (HDMTX)-based polychemotherapy and intracerebroventricular (ICV) chemotherapy via an Ommaya reservoir in elderly patients with primary central nervous system lymphoma (PCNSL). Methods:We performed a retrospective analysis on patients ⩾65...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420951087

    authors: Seidel S,Kowalski T,Margold M,Baraniskin A,Schroers R,Martus P,Schlegel U

    更新日期:2020-10-07 00:00:00

  • Best practice in the use of natalizumab in multiple sclerosis.

    abstract::Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612470401

    authors: Fernández O

    更新日期:2013-03-01 00:00:00

  • Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.

    abstract:OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285614563056

    authors: Hadden RD,Marreno F

    更新日期:2015-01-01 00:00:00

  • Vascular medicine and thrombectomy in stroke.

    abstract::The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285617742082

    authors: Fischer S,Weber W

    更新日期:2017-11-22 00:00:00

  • Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.

    abstract::The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early t...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285614549554

    authors: Freedman MS

    更新日期:2014-11-01 00:00:00

  • Recent developments in MOG-IgG associated neurological disorders.

    abstract::In the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica spectrum disorders or multiple sclerosis. The meticulous clinical des...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286420945135

    authors: Hegen H,Reindl M

    更新日期:2020-07-31 00:00:00

  • Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

    abstract::For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609344375

    authors: Awad A,Stüve O

    更新日期:2009-11-01 00:00:00

  • Treatment of neuromyelitis optica: current debate.

    abstract::Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that largely affects optic nerves and spinal cord. Recent studies have identified an elevation of serum anti-aquaporin 4 antibody as a hallmark of NMO. Typical cases of NMO significantly differ from multiple sclerosis (MS) in immunological markers, hi...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608093978

    authors: Okamoto T,Ogawa M,Lin Y,Murata M,Miyake S,Yamamura T

    更新日期:2008-07-01 00:00:00

  • Current and future treatments for Alzheimer's disease.

    abstract::Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three choline...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612461679

    authors: Yiannopoulou KG,Papageorgiou SG

    更新日期:2013-01-01 00:00:00

  • Therapy with cladribine is efficient and safe in patients previously treated with natalizumab.

    abstract:Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419887596

    authors: Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

    更新日期:2019-12-02 00:00:00

  • Capsaicinoids in the treatment of neuropathic pain: a review.

    abstract::The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285613501576

    authors: Peppin JF,Pappagallo M

    更新日期:2014-01-01 00:00:00

  • The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio.

    abstract::Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgro...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285615601360

    authors: Safouris A,Triantafyllou N,Parissis J,Tsivgoulis G

    更新日期:2015-11-01 00:00:00

  • Effective and safe diet therapies for Lennox-Gastaut syndrome with mitochondrial dysfunction.

    abstract:Background:Lennox-Gastaut syndrome (LGS) is a typical intractable form of epilepsy that most often occurs between the second and sixth year of life. This study aimed to evaluate the clinical efficacy and safety of ketogenic diet therapies (DTs) for LGS with mitochondrial dysfunction. Methods:This was a retrospective s...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419897813

    authors: Na JH,Kim HD,Lee YM

    更新日期:2020-02-06 00:00:00